Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$6.34
$0.75(19.28%)
At close: 4:00 PM EDT
$6.34
$0.75(19.28%)
Day’s Range― - ―
52-Week Range$0.98 - $6.83
Previous Close$4.6
Volume1.86M
Average Volume (3M)514.37K
Market Cap
$433.33M
Enterprise Value$390.30
Total Cash (Recent Filing)$151.76M
Total Debt (Recent Filing)$17.65M
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding65,075,350
10 Day Avg. Volume713,597
30 Day Avg. Volume514,373
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside26.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthRevenue is scaling quickly from collaboration and licensing activity, indicating increasing commercial engagement and potential validation of Prelude’s oncology platform, although the current base remains relatively small.
Very High Gross MarginThe strong gross margin on reported revenue suggests favorable economics for collaboration-related activities and potential future partnered products, providing operating leverage if revenue expands materially.
Conservative Balance SheetModest leverage and a larger equity base provide financial flexibility for continued research and development. This reduces balance-sheet pressure while Prelude advances its pipeline and seeks additional funding.
Bears Say
Persistent Operating LossesPrelude remains far from profitability despite revenue growth. Sustained operating and net losses can require repeated financing, dilute shareholders, and limit the company’s ability to independently fund development.
Ongoing Cash BurnCash consumption has improved from prior years but remains substantial and is not self-sustaining. Continued negative free cash flow leaves Prelude dependent on funding availability to maintain research and development.
No Recurring Product RevenueThe company lacks an established commercial revenue base, making financial results dependent on collaborations, milestones, and licensing events. This creates revenue uncertainty until a product reaches successful commercialization.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.98 and its highest was $6.83 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $433.33M.
When is Prelude Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Prelude Therapeutics’s earnings last quarter?
Currently, no data Available
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 65,075,350 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (26.18% Upside)
$8.00 (26.18% Upside)
Blogger Sentiment
Bullish
PRLD Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
64.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$8.00
▲(26.18% Upside)
Technical Analysis
Ownership Overview
30.04% Insiders
1.95% Mutual Funds
48.93% Other Institutional Investors
14.90% Public Companies and
Individual Investors